Baylor College of Medicine: CAR T Cells Armed With IL-15 Show Promise in Treating Solid Cancers
November 28, 2024
November 28, 2024
HOUSTON, Texas, Nov. 28 (TNSres) -- The Baylor College of Medicine issued the following news:
A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). Researchers at Baylor College of Medicine and Texas Children's Cancer Center led the study, which tested chimeric antigen receptor (CAR) T cells enhanced with the protein interleukin-15 (IL-15).
A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). Researchers at Baylor College of Medicine and Texas Children's Cancer Center led the study, which tested chimeric antigen receptor (CAR) T cells enhanced with the protein interleukin-15 (IL-15).